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health-insurance systems in Japan are different from those in 
other countries, a consensus was reached regarding standard 
treatments for chemotherapy that induce nausea and vomit-
ing. Current evidence was collected by use of MEDLINE, 
from materials from meetings of the American Society of 
Clinical Oncology National Comprehensive Cancer Net-
work, and from European Society of Medical Oncology/
Multinational Association of Supportive Care in Cancer 
guidelines for antiemesis. Initially, 21 clinical questions (CQ) 
Abstract The purpose of this article is to disseminate 
the standard of antiemetic therapy for Japanese clinical 
oncologists. On the basis of the Appraisal of Guidelines for 
Research and Evaluation II instrument, which reflects evi-
dence-based clinical practice guidelines, a working group of 
the Japanese Society of Clinical Oncology (JSCO) reviewed 
clinical practice guidelines for antiemesis and performed a 
systematic review of evidence-based domestic practice guide-
lines for antiemetic therapy in Japan. In addition, because 
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were selected on the basis of CQs from other guidelines. 
Patients treated with highly emetic agents should receive a 
serotonin (5-hydroxytryptamine; 5HT3) receptor antagonist, 
dexamethasone, and a neurokinin 1 receptor antagonist. For 
patients with moderate emetic risk, 5HT3 receptor antagonists 
and dexamethasone were recommended, whereas for those 
receiving chemotherapy with low emetic risk dexamethasone 
only is recommended. Patients receiving high-emetic-risk 
radiation therapy should also receive a 5HT3 receptor antago-
nist. In this paper the 2010 JSCO clinical practice guidelines 
for antiemesis are presented in English; they reveal high 
concordance of Japanese medical circumstances with other 
antiemetic guidelines that are similarly based on evidence.
Keywords Antiemetic treatment · Cancer chemotherapy · 
Clinical practice guideline
Introduction
Recent developments in cancer chemotherapy have 
improved the survival of patients with a variety of malig-
nancies. However, antiemetic treatments for chemotherapy 
which induce nausea and vomiting (CINV) are critical for 
successful chemotherapy. Consensus and/or evidence-
based guidelines for antiemetic treatment in oncology have 
been issued by the National Comprehensive Cancer Net-
work (NCCN) [1], the Multinational Association of Sup-
portive Care in Cancer (MASCC)/European Society of 
Medical Oncology (ESMO) [2], and the American Society 
of Clinical Oncology (ASCO) [3]. However, application 
of these guidelines in Japan is limited because of differ-
ent clinical circumstances and different domestic insurance 
coverage. Hence the Japanese clinical practice guideline 
for antiemetics was established and published on May 1st, 
2010 as the first publication of the Japanese Society of 
Clinical Oncology (JSCO).
Methods
Initially, JSCO selected members of a working group 
for these guidelines on the basis of the Appraisal of 
Guidelines for Research and Evaluation (AGREE) II 
instrument [4], which assesses the methods used to 
generate evidence-based clinical practice guidelines. 
The members of a working group were included medi-
cal oncologists, oncological surgeons, palliative care 
physicians, and psycho-oncologists. The AGREE II 
Instrument is available as a PDF or in electronic form 
from http://www.agreetrust.org/resource-centre/agree-
ii/. A draft of the guidelines was developed systemati-
cally, and members of the medical staff were in unani-
mous agreement with regard to all recommendations 
for treatment and clinical questions (CQ). However, 
domestic factors including ethnicity and health policy 
formation at the system level required further consid-
eration. Hence, a consensus of all medical practitioners 
was held at a consensus meeting, and recommendations 
for antiemetic treatments were discussed in the context 
of Japanese medical circumstances.
Literature search strategy
A systematic review and meta-analysis of the effective-
ness of antiemetic therapy was performed by use of the 
major international guidelines NCCN, MASSC/ESMO, 
and ASCO as sources of information [1–3]. Subse-
quently, high-level evidence was selected from the litera-
ture, and structured abstracts were generated for each of 
the manuscripts included. MEDLINE searches were also 
performed to identify other randomized controlled tri-
als, and the Cochrane library was reviewed during 2008–
2010 [5]. Materials from ASCO and MASSC annual 
meetings were reviewed and some Japanese manuscripts 
containing sufficiently strong evidence were included. 
Materials that were available in abstract form only were 
not considered.
Inclusion criteria for published studies
Systematic reviews and reports of randomized controlled 
trials were included if the intervention was for treatment 
of nausea or vomiting after cancer therapy, and nausea 
and/or vomiting outcomes were reported. This guideline 
was reviewed and approved by the JSCO Clinical Practice 
Guidelines Committee and the Board of Directors, and was 
reviewed and approved for publication in the International 
Journal of Clinical Oncology.
Guidelines and conflicts of interest
The Update Committee was assembled in accordance 
with ASCO’s Conflict of Interest (COI) Management Pro-
cedures for Clinical Practice Guidelines (“Procedures”, 
summarized at http://www.asco.org/guidelinescoi). The 
members of the working group provided disclosure forms 
that required disclosure of financial and other interests to 
the board of directors of JSCO. Subsequently, the COI 
20 Department of Skin Oncology/Dermatology, Saitama 
Medical University International Medical Center, Saitama, 
Japan
21 Department of Surgery, Teikyo University School 
of Medicine, Tokyo, Japan
3Int J Clin Oncol (2016) 21:1–12 
1 3
committee reviewed the COI of each member and allowed 
all members without COIs to contribute to the guideline.
Recommendation grade
Recommendation grades were stated as follows:
A  Strongly recommended clinical action
B  Recommended clinical action
C1  Clinical action may be useful although there is a 
lack of high-level scientific evidence
C2  Not recommended because of insufficient scien-
tific evidence
D  Clinical action not recommended
Results
The working group of JSCO clinical practice guidelines 
for antiemesis adopted a clinical question (CQ) form as the 
main guideline format and selected the following 21 CQs:
CQ1. How is the emetic risk induced by cancer chemo-
therapy categorized?
Recommendation (Grade A): the emetic risk induced 
by cancer chemotherapy is classified as high, moderate, 
low, and minimum according to the frequency of patient 
nausea and vomiting experiences, and antiemetic prophy-
lactic treatments are prescribed in accordance with these 
categories.
The emetic risks of cancer chemotherapy depend on the 
potential emetogenicity of combined chemotherapeutic 
regimens. The emetic risk is evaluated on the basis of the 
percentage of untreated patients who experience acute eme-
sis within 24 h of initiation and/or administration of cancer 
chemotherapy and is categorized as follows:
High emetic risk: 90 % or more patients experience 
acute emesis
Moderate emetic risk: 30–90 % of patients experience 
acute emesis
Low emetic risk: 10–30 % of patients experience acute 
emesis
Minimum emetic risk: fewer than 10 % of patients expe-
rience acute emesis
CQ2. How are intravenous chemotherapeutic agents cat-
egorized for the emetic risk?
Recommendation (Grade A): proper and sufficient 
antiemetic prophylaxis should be recommended in accord-
ance with the four risk categories (Table 1).
Recommendation (Grade C1): antiemetic treatments for 
domestic chemotherapeutic agents developed in Japan are 
uncertain because of limited evidence of drug efficacy and 
low frequency of usage.
Emetic risks of chemotherapeutic agents are classified 
in Table 1 on the basis of the recommendations of exist-
ing guidelines produced with a high level of consensus, for 
example NCCN, MASSC, and ASCO; they were modi-
fied in consideration of particular clinical circumstances in 
Japan [6, 7]. Most chemotherapeutic regimens with high or 
moderate emetic risk include intravenous chemotherapeutic 
agents, and proper and flexible management of their emetic 
risks is essential because they are usually administered over 
several days and include several drugs. Although the 2009 
NCCN guidelines indicate that high and low-dose cisplatin 
regimens have high and moderate emetic risk, respectively, 
the 2008 MASCC and 2006 ASCO guidelines categorized 
cisplatin as a drug of high emetic risk irrespective of dos-
age [8, 9]. Accordingly, all cisplatin regimens, including 
those administered over several days were regarded as regi-
mens of high emetic risk (CQ10). However, combined regi-
mens that include anthracycline and cyclophosphamide, 
for example AC, CAF, EC, and FEC, are usually regarded 
as having high emetogenicity. The 2009 NCCN guidelines 
categorized these anthracycline-containing regimens as 
high emetic risk similar to other monotherapeutic agents 
with high emetogenicity. Hence, this categorization was 
used for all anthracycline-containing regimens.
CQ3. How are the emetic risk categories for oral chemo-
therapeutic agents defined and managed?
Recommendation (Grade C1): according to clinical 
study protocols designed to assess efficacy as supportive 
co-treatments, suspension and/or dose reduction of chemo-
therapeutic agents should be considered to limit nausea and 
vomiting to grade 3 or less.
The emetic risk of oral chemotherapeutic agents is listed 
in Table 2. In Japan, oral fluoropyrimidine-based regimens 
are frequently used as adjuvant treatments with tegafur-ura-
cil and/or leucovorin and capecitabine for colorectal cancer, 
S-1 for gastric cancer, and tegafur-uracil for breast and lung 
cancers, and several clinical trials have demonstrated effi-
cacy is reasonable. Moreover, the Japanese clinical practice 
guidelines have indicated that S-1 and tegafur-uracil and/or 
leucovorin are efficacious treatment strategies for advanced 
gastric and colorectal cancers. Although these oral chemo-
therapeutic agents have lower emetogenicity when admin-
istered alone, adverse digestive events occur after repeated 
daily administration. Hence, antiemetic treatments are 
important to achieving higher drug adherence and to opti-
mizing treatment.
CQ4. How should acute nausea and vomiting induced by 
cancer chemotherapy be prevented?
Recommendation (Grade A): a triple regimen of neu-
rokinin 1 (NK1) receptor antagonist (aprepitant), seroto-
nin (5-hydroxytryptamine: 5HT3) receptor antagonist, and 
dexamethasone is recommended for acute emesis during 
highly emetic cancer chemotherapy.
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Recommendation (Grade A): regimens containing 5HT3 
receptor antagonists and dexamethasone are basically recom-
mended for acute emesis during moderately emetic cancer 
chemotherapy. For particular chemotherapeutic regimens, 
addition of an NK1 receptor antagonist to regimens of 5HT3 
receptor antagonist and dexamethasone are considered.
Table 1  Emetic risk category for intravenous chemotherapeutic agents
Agents in italics are not approved for clinical use in Japan
JSCO emetic risk category Agent (regimen)
High emetic risk (emetic frequency >90 %) Cisplatin Altretaine
Cyclophosphamide (>1500 mg/m2) Carmustine (>250 mg/m2)
Dacarbazine Mechlorethamine
Doxorubicin + cyclophosphamide Streptozocin
Epirubicin + cyclophosphamide
Moderate emetic risk (emetic frequency 30–90 %) Actinomycin D Irinotecan
Amrubicin Melphalan (≥50 mg/m2)
Arsenic trioxide Methotrexate (≥250 mg/m2)
Busulfan (>4 mg/day) Nedaplatin
Carboplatin Oxaliplatin (≥75 mg/m2)
Cyclophosphamide (≤1500 mg/m2) Temozolomide
Cytarabine (>200 mg/m2) Therarubicin
Daunorubicin Amifostine (≥300 mg/m2)
Doxorubicin Azacitidine
Enocitabine Bendamustine
Epirubicin Carmustine (≤250 mg/m2)
Idarubicin Clofarabine
Ifosphamide
Interferon α (≥10 million IU/m2)
Interleukin-2 (>12–15 million IU/m2)
Low emetic risk (emetic frequency 10–30 %) Interleukin-2 (≤12 million IU/m2) Mitoxantrone





Interferon α (5–10 million IU/m2) Ranimusutine
Liposomal doxorubicin Topotecan
Methotrexate (50–250 mg/m2) Amifostine (<300 mg)
Mitomycin C Ixabepilone






Cytarabine (<100 mg/m2) Decitabine
Fludarabine Denileukin diftitox
Gemtuzumab ozogamicin Dexrazoxane
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Acute onset of nausea and vomiting occurs within 
a few minutes to several hours, and intensity generally 
peaks from 5 to 6 h after administration of chemotherapy 
and usually recovers within 24 h. Management and con-
trol of CINV are essential for successful cancer chemo-
therapy, because unfavorable side effects of nausea and 
vomiting are associated with poor treatment adherence 
and effects. In addition, incomplete prevention of acute 
emesis may lead to uncontrollable delayed emesis [10]. 
Hence, according to the four emetic risk categories indi-
cated in CQ2 and 3, appropriate and sufficient antiemetic 
treatments are needed from the start of chemotherapy. 
The standard model of antiemetic treatment regimens is 
detailed in the four diagrams in Fig. 1. In the high emetic 
risk diagram, evidence of antiemetic actions of AC regi-
mens was taken from clinical trials of other highly emetic 
cancer agents, and suggests no additional effects of 
dexamethasone after day 2. Upon issue of the 1st guide-
line, oral aprepitant was the only NK1 receptor antago-
nist available for clinical use in Japan. Subsequently, in 
November 2011, the Japanese Ministry of Health, Labour, 
and Welfare approved the intravenous NK1 receptor 
antagonist, fosaprepitant. Accordingly, we immediately 
modified the diagram and included additional information 
about fosaprepitant as a minor revision of the guideline, 
with careful consideration of the limited evidence of its 
efficacy and safety.
CQ5. How should delayed nausea and vomiting after 
cancer chemotherapy be prevented?
Recommendation (Grade A): a combined regimen of 
NK1 receptor antagonist (aprepitant) and dexamethasone 
is recommended for treatment of delayed emesis during 
highly emetic cancer chemotherapy.
Recommendation (Grade A): single administration of 
dexamethasone is basically recommended for delayed eme-
sis during moderately emetic cancer chemotherapy. How-
ever, regimens of NK1 antagonist and/or dexamethasone 
are considered.
Delayed onset of nausea and vomiting occurs later than 
24 h after administration of chemotherapy. In these cir-
cumstances, control of delayed emesis is essential to main-
taining patients’ quality of life and for motivating further 
treatment with a healthy mentality. As described in CQ4, 
complete prevention of acute emesis is the most important 
and fundamental strategy for preventing delayed emesis 
(Fig. 1). In specific cases in which dexamethasone should 
be restricted, 2–4 days of 5HT3 antagonist is recommended 
instead of dexamethasone.
CQ6. What kinds of serotonin (5HT3) receptor antago-
nist are available in Japan?
Recommendation (Grade A): 5HT3 receptor antagonists 
are effective treatments for prevention of nausea and vomit-
ing during cancer chemotherapy; seven drugs are approved 
in Japan: granisetron, palonosetron, ramosetron, ondanse-
tron, tropisetron, azasetron, and indisetron.
Several 5HT3 receptor antagonists are currently avail-
able in Japan, and efficacy for management of CINV has 
been demonstrated for all these agents, particularly under 
conditions of acute phase emesis. However, the efficacy 
of these agents for treatment of delayed emesis remains 
controversial because no further antiemetic effects of 
additional treatments have been observed after initial use 
Table 2  Emetic risk category for oral chemotherapeutic agents
Agents in italics are not approved for clinical use in Japan
JSCO emetic risk category Agent (regimen)
High emetic risk (emetic frequency >90 %) Procarbazine
Moderate emetic risk (emetic frequency 30–90 %) Cyclophosphamide Temozolomide
Etoposide Vinorelbine
Imatinib
Low emetic risk (emetic frequency 10–30 %) Capecitabine S-1
Doxifluridine Sobuzoxane Tegafur-Uracil (UFT)
Mercaptopurine
Nilotinib
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of 5HT3 receptors with antagonistic agents. It has been 
proved that palonosetron is not inferior to granisetron 
in the acute phase and is superior to granisetron in the 
delayed phase [11].
CQ7. What is the recommended dose of corticosteroid 
for antiemetic treatment?
Recommendation (Grade A): corticosteroid is an 
effective antiemetic at recommended doses determined 
Fig. 1  Antiemetic treatments 
for intravenous cancer chemo-
therapy. a High emetic risk: 
in the absence of aprepitant, 
13.2–16.4 mg dexametha-
sone should be given on day 
1; b moderate emetic risk; c 
low emetic risk; d minimum 
emetic risk. Asterisk, optional 
fosaprepitant was added to the 
diagrams in a revised edition 
(version 1.2). Double asterisk, 
optional dose of dexametha-
sone. The diagrams indicate 
standard examples of antiemetic 
treatment regimens. Flexible 
modifications are necessary 
according to specific condi-
tions of each patient. Intrave-
nous dexamethasone contains 
3.3 mg/mL dexamethasone out 
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according to the emetic risk categories of chemotherapeutic 
regimens.
Corticosteroid has been used as an antiemetic pro-
phylactic during cancer chemotherapy for 25 years [12], 
although its mechanism of action remains unclear com-
pared with those of 5HT3 and NK1 antagonists, which 
have recently been approved with clear evidence of mecha-
nisms. Although several classes of corticosteroid are avail-
able, dexamethasone and methylprednisolone are most fre-
quently used as antiemetics, with strong evidence of their 
effects [13, 14]. In particular, oral and intravenous dexa-
methasone (4–20 mg/day) has been approved as antiemetic 
treatment during cancer chemotherapy in Japan. However, 
the efficacy of high-dose dexamethasone has not been 
compared with that of 20-mg treatments among either 
Western [13, 14] or Japanese populations [15].
CQ8. How should breakthrough nausea and vomiting be 
managed?
Recommendation (Grade B): fixed around-the-clock 
administration of a variety of drugs should be considered 
according to patient symptoms. In addition, antiemetic 
5HT3 receptor antagonists should be replaced with another 
type of 5HT3 receptor antagonist.
Breakthrough emesis refers to nausea and vomiting 
despite prophylactic antiemetic treatment, and requires 
additional treatment with antiemetic agents with mech-
anisms of action that differ from that of the primary 
antiemetic agent. Among these, the dopamine antagonists 
metoclopramide, butyrophenone, corticosteroid, and loraz-
epam may be considered for breakthrough emesis, despite 
poor evidence of their efficacy. A systematic review of 
antiemetic treatments for patients with advanced cancer 
showed that metoclopramide is superior to placebo and 
equivalent to ondansetron, although responses were only 
23–36 % and 18–52 % for nausea and vomiting, respec-
tively [16]. Moreover, a randomized clinical controlled 
study of 51 advanced cancer patients showed no significant 
effects of additional dexamethasone for nausea after failure 
of antiemetic response to metoclopramide [17].
Some reports recommend antiemetic prophylaxis using 
agents that are not 5HT3 receptor antagonists.
CQ9. How should acute nausea and vomiting induced by 
low and minimum emetic chemotherapy be managed?
Recommendation (Grade B): during low emetic chemo-
therapy, dexamethasone should be considered according to 
chemotherapeutic regimen and patient background.
Recommendation (Grade C1): routine usage of dexa-
methasone is not recommended for minimum emetic 
chemotherapy.
Prophylactic antiemetic treatment is not recommended 
for low or minimum emetic chemotherapy, because patients 
do not progress to definite nausea and vomiting. Nonethe-
less, some patients suffer from emesis during treatment 
with low or minimum emetic chemotherapy, necessitating 
flexible and appropriate treatment despite the absence of 
high-level evidence. The 2006 ASCO and 2008 MASCC 
guidelines recommended administration of 4–8 mg dexa-
methasone [13, 18], and include prochlorperazine [19] and 
metoclopramide as optional antiemetics.
CQ10. How is nausea and vomiting managed for such 
regimens as several cisplatin treatments daily?
Recommendation (Grade B): a triple antiemetic regi-
men of 5HT3 antagonist, dexamethasone, and aprepitant is 
recommended for acute nausea and vomiting during more 
typical chemotherapeutic regimens. A double regimen of 
dexamethasone and aprepitant is recommended for delayed 
nausea and vomiting, even during regimens of several cis-
platin treatments daily.
It is widely accepted that cisplatin is a highly emetic 
chemotherapeutic agent, and it is commonly administered 
every 3 or 4 weeks at ≥50 mg/m2 for treatment of a vari-
ety of malignancies. However, different cisplatin regimens 
have been established with reasonable evidence, includ-
ing several cisplatin treatments daily at <50 mg/m2 for 
oncologic tumors such as cholangiocarcinomas, bladder 
cancers, and germinomas [20, 21], and continuous cispl-
atin injections at 100 mg/m2 over 4 days for non-Hodgkin 
malignant lymphomas.
CQ11. How should anticipatory nausea and vomiting be 
managed?
Recommendation (Grade B): initially, complete preven-
tion of emesis is essential during acute and delayed phases, 
so patients never experience nausea and vomiting.
Recommendation (Grade B): benzodiazepine is effective 
for anticipatory nausea and vomiting.
Recommendation (Grade B): such psychological therapy 
as systematic desensitization and/or behavioral treatment, 
relaxation therapy, and hypnotherapy for pediatric patients 
effectively ameliorate anticipatory nausea and vomiting.
Anticipatory nausea and vomiting occurs immediately 
before treatment, and reflects previous negative experi-
ences of cancer chemotherapy [22–24], although nausea is 
more common than vomiting among such cases. The ideal 
prophylaxis for this symptom is complete prevention of 
emesis from the initial treatment [23–26]. Hence, appropri-
ate antiemetic treatments are essential, and require accurate 
assessment of emetic risks for planned chemotherapeutic 
regimens. The 2009 NCCN and 2008 MASCC guidelines 
recommended treatments with lorazepam [27] for anticipa-
tory nausea and vomiting, and alprazolam [28] for anticipa-
tory nausea.
CQ12. How are emetic risks categorized for radiation 
therapy?
Recommendation (Grade A): emetic risks of radiation 
therapy are classified (Table 3) according to tissue targets 
and volumes for irradiation.
8 Int J Clin Oncol (2016) 21:1–12
1 3
As for chemotherapy, antiemetic treatments for radiation 
therapy are critical for successful treatment. Accordingly, 
the 2004 MASCC and 2006 ASCO guidelines indicate 
the emetic risk categories for specific targeted tissues, and 
recommend prophylactic emetic regimens based on these 
risk classifications. The risk of radiation-induced nausea 
and vomiting is categorized according to the percentage 
of patients who experience emesis. Moreover, whole body 
and upper abdominal radiation therapy are likely to cause 
greater emesis, and the frequency of nausea and vomiting 
increases with larger total doses and target tissue volumes 
[29, 30].
CQ13. Do antiemetic treatments differ in equivalent reg-
imens from those in standard regimens containing specific 
key agents?
Recommendation (Grade C1): the emetic risk should be 
assessed on the basis of the agent with the highest emetic 
risk, even for similar chemotherapeutic regimens that com-
prise several agents.
Most clinically used chemotherapeutic regimes include 
several drugs, although many variations of standard chemo-
therapeutic regimens containing similar key agents. Thus, it 
is important to assess the emetic risks of regimens accord-
ing to the emetic risks of each agent in isolation.
CQ14. What clinical factors and patient backgrounds 
affect CINV?
Recommendation (Grade C1): treatment and patient 
factors affect the emetic risks of CINV. Treatment factors 
include emetogenicity and dosages of chemotherapeutic 
agents, and tissue targets and volumes of radiation therapy. 
Relevant patient factors include age, gender, and alcohol 
consumption.
The frequency and intensity of emesis from CINV are 
affected by numerous factors, including specific chemo-
therapeutic agents, regimens, dosages, schedules, routes of 
administration, and tissue targets and volumes for radiation 
therapy. In addition, patient factors such as age [31], gen-
der [31, 32], alcohol consumption [33], and experience of 
nausea gravidarum affect the emetic effects of CINV. The 
NCCN guideline also suggests that bowel obstruction, ves-
tibulopathy, brain metastasis, electrolyte dysbolism, ure-
mia, opioid use, gastric atony, and mental disorders are 
potential risk factors for emesis. Accordingly, management 
of treatment-related emesis is well-established with con-
sensus, whereas patient-oriented factors remain unclear.
CQ15. How should CINV be managed in pediatric 
patients with malignancies?
Recommendation (Grade C1): multidisciplinary man-
agement using 5HT3 receptor antagonists, corticosteroid, 
and other antiemetic agents control the emetic effects of 
CINV, even for pediatric patients.
In the last three decades, advances in cancer treatment, 
for example high dose methotrexate, cytarabine, cyclophos-
phamide, and hematinic stem cell transplantation, have led 
to long term prognoses for ≥70 % of pediatric patients with 
malignancies. However, there are only a few reports with 
high level evidence about antiemetic treatment in pediat-
ric patients from western populations [34–36]. Accord-
ingly, they are treated with modified dosage on the basis of 
results of clinical trials on adult patients. Proper antiemetic 
treatments also enable pediatric patients to receive cancer 
chemotherapy without decline in QOL.
CQ16. Is it possible to discriminate nausea from ano-
rexia, pyrosis, and dyspepsia? Which diseases produce 
symptoms of nausea and vomiting?
Recommendation (Grade B): no definitive evidence dis-
tinguishes nausea from anorexia, pyrosis, and dyspepsia. 
However, proton pump inhibitors (PPI) and H2 blockers are 
recommended for patients with these symptoms.
Recommendation (Grade C1): antiemetic agents should 
be used on the basis of accurate assessment of patient 
conditions.
Symptoms of anorexia, pyrosis, and dyspepsia are 
caused by several factors related to digestive dysfunction, 
and are frequently accompanied with nausea and other 
symptoms. Therefore, nausea induced by chemotherapy 
has not been strictly distinguished from other symptoms of 
digestive dysfunction. Nonetheless, PPI and H2-blockers 
are recommended as optional treatments for these symp-
toms [37].
In addition to treatments for CINV, patients with malig-
nancies may suffer from nausea and vomiting as a result of 
the following conditions:
–– Partial or complete bowel obstruction
–– Vestibulopathy
Table 3  Emetic risk category 
for radiation therapy
JSCO emetic risk category Treated area
High emetic risk (emetic frequency: >90 %) Total body
Moderate emetic risk (emetic frequency: 30–90 %) Upper abdomen
Low emetic risk (emetic frequency: 10–30 %) Lower thorax Pelvis
Cranium (radiosurgery) Craniospinal
Minimum emetic risk (emetic frequency: <10 %) Head and neck Extremities
Cranium Breast
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–– Brain metastasis
–– Electrolyte dysbolism (hypercalcemia, hyponatremia, 
and hyperglycemia)
–– Uremia
–– Other combinations of drugs, including opioids
–– Gastric atony
–– Anticipatory nausea and vomiting
CQ17. How are different forms of agents appropriately 
selected and used?
Recommendation (Grade B): patients should self-man-
age the use of oral agents. However, in circumstances in 
which nausea and vomiting prevent patients from taking 
oral treatments, optional intravenous administration should 
be considered.
Antiemetic agents are available in a variety of formula-
tions for oral, rectal, intravenous, and intramuscular adminis-
tration. A meta-analysis of randomized control trials showed 
equivalence of oral and intravenous 5HT3 receptor antago-
nists [38]. However, the cost effectiveness and convenience 
of administration of oral agents are superior to those of intra-
venous agents, particularly when administered as tablets that 
disintegrate orally. Nonetheless, intravenous agents may 
improve treatment adherence among pediatric patients.
CQ18. For which antiemetic drugs are pharmacokinetic 
interactions observed?
Recommendation (Grade B): it is essential that aprepi-
tant is used carefully to avoid interactions with co-admin-
istered drugs, including some chemotherapeutic agents. 
Moreover, strict dose control of combined drug regimens 
according to patient conditions and disease backgrounds is 
critical.
Because aprepitant induces and inhibits the cytochrome 
P450 enzymes 3A4 (CYP3A4) and 2C9 (CYP2C9) it can 
alter plasma concentrations of co-administered drugs by 
interacting with these critical drug-metabolizing enzymes 
[39]. Chemotherapeutic agents that are metabolized by 
CYP3A4 include docetaxel, paclitaxel, etoposide, irinote-
can, ifosphamide, imatinib, vinorelbine, vinblastine, and 
vincristine. Although doses were not adjusted for several 
chemotherapeutic agents used concurrently with aprepitant 
in phase III trials, these drugs should be used with cau-
tion [40, 41] because aprepitant interacts with several non-
chemotherapeutic drugs, including warfarin, dexametha-
sone, and methylprednisolone. Concurrent use of aprepitant 
temporarily reduces prothrombin time–international nor-
malized ratio (PT–INR) for patients receiving regimens 
that contain warfarin, necessitating anticoagulant monitor-
ing for these patients [42]. Aprepitant also increases AUCs 
of the corticosteroids dexamethasone and methylpredniso-
lone, necessitating appropriate reductions of corticosteroid 
doses (CQ7) [39]. However, to ensure anti-cancer effects, 
steroid doses should not be reduced in chemotherapeutic 
regimens for malignant lymphoma that include corticoster-
oid, despite concomitant use of aprepitant. Moreover, con-
current use of the CYP3A4 inhibitors ketoconazole, itra-
conazole, and erythromycin may increase aprepitant AUCs, 
whereas the CYP3A4 inducers carbamazepine, rifampicin, 
and phenytoin may reduce plasma levels of aprepitant.
CQ19. How are the effects of antiemetic treatment 
evaluated?
Recommendation (Grade A): the effects of antiemetic 
treatment should be assessed at every visit for outpatients, 
and within 24 h after administration of chemotherapy for 
admitted patients.
Recommendation (Grade C1): strict assessments require 
patients to report their conditions to medical staff by using 
self-reporting systems.
No definitive evidence or consensus has been published 
for assessment of antiemetic treatments. However, success-
ful anticancer treatment depends on optimum patient assess-
ments, and nausea and vomiting are observed for 31 and 
20 % of cancer patients, respectively [43]. Accordingly, the 
2009 NCCN guidelines for palliative care recommend opti-
mum screening for supportive care of all oncology patients 
according to their symptoms throughout the entire clinical 
course. Moreover, the RAND Cancer Quality-Assessing 
Symptoms Side Effects and Indicators of Supportive Treat-
ment Project recommends symptom evaluations for all 
cancer patients, at every outpatient visit, and within 24 h 
of hospital admission. The 2009 NCCN Clinical Prac-
tice Guidelines for Antiemetics in Oncology suggest that 
prevention of nausea and vomiting is a primary objective. 
Hence, prophylactic treatment is mandatory for ≥4 days, 
because the emetic risks of CINV continue for several 
days under conditions of highly or moderately emetogenic 
cancer chemotherapy [44]. Moreover, complete responses 
were reportedly not achieved for acute and delayed emesis, 
despite optimum prophylactic treatment [40].
Differential diagnosis of the causes of emesis are nec-
essary during clinical evaluations (CQ14, 16). However, 
common terminology criteria for adverse events (CTCAE) 
may remain useful when chemotherapeutic regimens are 
applied, and are based on objective assessments by medi-
cal staff rather than subjective assessments by patients. 
Nonetheless, applicable patient directed subjective evalua-
tions include the numerical rating scale (NRS), the visual 
analog scale (VAS), the verbal rating scale (VRS) and the 
Wong–Baker face rating scale. In addition, index of nau-
sea, vomiting and retching (INVR) [44], Morrow assess-
ment of nausea and emesis (MANE) [45], and functional 
living index-emesis (FLIE) scores [46] are also applicable 
as tools for evaluating longitudinal changes in emesis and 
the ensuing effects on quality of life.
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CQ20. How is occlusive ileus managed in cancer 
patients with advanced and metastatic status, including car-
cinomatous peritonitis?
Recommendation (Grade A): reduction of gastroin-
testinal pressure using a nasogastric tube or percutaneous 
gastrostomy is recommended. In addition, intraperitoneal 
injection of octreotide is recommended as a drug therapy 
for carcinomatous peritonitis.
Recommendation (Grade C1): such salvage surgery as 
bowel bypass may also be effective for patients who are not 
in a critical condition and have expectations of compara-
tively long survival. However, endoscopic stents are recom-
mended to resolve symptoms of simple intestinal obstruc-
tion for patients with poor prognosis.
Bowel obstruction among patients with advanced meta-
static disease reduces quality of life and causes difficulty 
in the continuation of anticancer treatments. Conserva-
tive treatments are usually used for such patients, because 
of poor prognosis as a result of advanced oncological sta-
tus. However, 50 % of colon cancer patients and 6–34 % 
of gynecologic cancer patients suffer from benign bowel 
obstructions [47], so accurate diagnoses is required.
CQ21. How are opioid-induced nausea and vomiting 
managed?
Recommendation (Grade B): emesis that is induced by 
opioid use should be managed by use of antiemetic treat-
ments, although opioid rotation or changes in routes of 
administration may be considered.
Recommendation (Grade C1): prophylactic antiemetic 
treatments during opioid therapy may be useful despite the 
lack of high-level evidence of efficacy and safety.
The WHO ladder strongly recommends opioid use for 
oncological pain and cites high-level evidence of efficacy 
and safety. Moreover, three opioid receptors, the δ and κ 
receptors for emetogenic functions and the μ receptor for 
antiemetic functions, have been characterized. Patients 
frequently suffer from constipation, sleepiness, nausea, 
and vomiting on initiation of opioid therapy. However, 
antiemetic treatments for opioid-induced emesis are impor-
tant for successful pain control among cancer patients. 
Moreover, differential diagnosis of other causes is impor-
tant in patients suffering from emesis after opioid treat-
ments (CQ16). Nonetheless, opioid-induced emesis is usu-
ally relieved within a few days of opioid administration.
Discussion
The purpose of these practice guidelines is to disseminate 
treatment recommendations for daily practice according 
to CQ relating to medications. Thus, 21 CQ pertaining to 
antiemetic therapy, including prophylactic and retrospec-
tive antiemetic treatments, were generated. In this literature 
review, most of the evidence was collected from foreign 
studies reporting high-level evidence that was acceptable 
for Japanese cancer patients. Therefore, these recommenda-
tions for standard therapy, depending on the grade of rec-
ommendation, were made on the basis of systematic review 
and meta-analysis of antiemetic therapy. Consequently, the 
CQs and their recommendations were similar to those pub-
lished in previous guidelines that have been used globally. 
However, most reported evidence fails to consider ethnicity 
and Japanese health-care systems. Thus, after release of the 
guidelines, their penetration and dissemination to Japanese 
medical practitioners was evaluated. To this end, current use 
of antiemetic treatment in Japan was analyzed on the basis 
of data obtained from a nationwide questionnaire. Response 
was 88 % and use of the guidelines 78 % (in press).
Conclusion
In this manuscript we present, in English, of the 2010 JSCO 
clinical practice guidelines for antiemesis. High concord-
ance with other antiemetic guidelines reflected their evi-
dence-based nature. After release of these guidelines, high 
recognition and penetration was achieved for antiemetic 
medicine in Japan, thus contributing to effective antiemetic 
therapy for Japanese patients with malignancies.
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